In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA

Mitsuo Yoshinouchi, Taketo Yamada, Masahiro Kizaki, Jin Fen, Takeyoshi Koseki, Yasuo Ikeda, Tatsuji Nishihara, Kenji Yamato

Research output: Contribution to journalArticle

152 Citations (Scopus)

Abstract

Human papillomavirus type 16 (HPV16), a causative agent of cervical cancers, encodes the E6 and E7 oncogenes, whose simultaneous expression is pivotal for malignant transformation and maintenance of malignant phenotypes. In the hope of developing a gene-specific therapy for HPV-related cancer, we examined the effects of E6 short-interfering RNA (siRNA) on the expression of these oncogenes and on the cell growth of HPV16-related cervical cancer cells. Using SiHa cervical cancer cells, we demonstrated that E6 siRNA decreased the levels of mRNA encoding E6 as well as that encoding E7 protein and also induced nuclear accumulation of p53, the most important target of E6. E6 siRNA suppressed monolayer and anchorage-independent growth of SiHa cells, which was associated with p21CIP1/WAF1 induction and hypophosphorylation of retinoblastoma protein. Further, SiHa cells treated with E6 siRNA formed tumors in NOD/SCID mice that were significantly smaller than in those treated with control siRNA. Our results show HPV E6 siRNA as a candidate for gene-specific therapy for HPV-related cervical cancer.

Original languageEnglish
Pages (from-to)762-768
Number of pages7
JournalMolecular Therapy
Volume8
Issue number5
DOIs
Publication statusPublished - 2003 Nov

Fingerprint

Human papillomavirus 16
Uterine Cervical Neoplasms
Small Interfering RNA
Growth
Second Primary Neoplasms
Oncogenes
Genetic Therapy
Retinoblastoma Protein
Inbred NOD Mouse
SCID Mice
In Vitro Techniques
Maintenance
Phenotype
Messenger RNA
Neoplasms
Proteins

Keywords

  • Cell growth
  • E6
  • E7
  • HPV16
  • NOD/SCID mouse
  • p53
  • Rb
  • RNAi
  • siRNA
  • Tumor formation

ASJC Scopus subject areas

  • Molecular Biology

Cite this

Yoshinouchi, M., Yamada, T., Kizaki, M., Fen, J., Koseki, T., Ikeda, Y., ... Yamato, K. (2003). In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. Molecular Therapy, 8(5), 762-768. https://doi.org/10.1016/j.ymthe.2003.08.004

In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. / Yoshinouchi, Mitsuo; Yamada, Taketo; Kizaki, Masahiro; Fen, Jin; Koseki, Takeyoshi; Ikeda, Yasuo; Nishihara, Tatsuji; Yamato, Kenji.

In: Molecular Therapy, Vol. 8, No. 5, 11.2003, p. 762-768.

Research output: Contribution to journalArticle

Yoshinouchi, M, Yamada, T, Kizaki, M, Fen, J, Koseki, T, Ikeda, Y, Nishihara, T & Yamato, K 2003, 'In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA', Molecular Therapy, vol. 8, no. 5, pp. 762-768. https://doi.org/10.1016/j.ymthe.2003.08.004
Yoshinouchi, Mitsuo ; Yamada, Taketo ; Kizaki, Masahiro ; Fen, Jin ; Koseki, Takeyoshi ; Ikeda, Yasuo ; Nishihara, Tatsuji ; Yamato, Kenji. / In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA. In: Molecular Therapy. 2003 ; Vol. 8, No. 5. pp. 762-768.
@article{88daf16e5e0048b79ed4265122160d46,
title = "In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA",
abstract = "Human papillomavirus type 16 (HPV16), a causative agent of cervical cancers, encodes the E6 and E7 oncogenes, whose simultaneous expression is pivotal for malignant transformation and maintenance of malignant phenotypes. In the hope of developing a gene-specific therapy for HPV-related cancer, we examined the effects of E6 short-interfering RNA (siRNA) on the expression of these oncogenes and on the cell growth of HPV16-related cervical cancer cells. Using SiHa cervical cancer cells, we demonstrated that E6 siRNA decreased the levels of mRNA encoding E6 as well as that encoding E7 protein and also induced nuclear accumulation of p53, the most important target of E6. E6 siRNA suppressed monolayer and anchorage-independent growth of SiHa cells, which was associated with p21CIP1/WAF1 induction and hypophosphorylation of retinoblastoma protein. Further, SiHa cells treated with E6 siRNA formed tumors in NOD/SCID mice that were significantly smaller than in those treated with control siRNA. Our results show HPV E6 siRNA as a candidate for gene-specific therapy for HPV-related cervical cancer.",
keywords = "Cell growth, E6, E7, HPV16, NOD/SCID mouse, p53, Rb, RNAi, siRNA, Tumor formation",
author = "Mitsuo Yoshinouchi and Taketo Yamada and Masahiro Kizaki and Jin Fen and Takeyoshi Koseki and Yasuo Ikeda and Tatsuji Nishihara and Kenji Yamato",
year = "2003",
month = "11",
doi = "10.1016/j.ymthe.2003.08.004",
language = "English",
volume = "8",
pages = "762--768",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",
number = "5",

}

TY - JOUR

T1 - In vitro and in vivo growth suppression of human papillomavirus 16-positive cervical cancer cells by E6 siRNA

AU - Yoshinouchi, Mitsuo

AU - Yamada, Taketo

AU - Kizaki, Masahiro

AU - Fen, Jin

AU - Koseki, Takeyoshi

AU - Ikeda, Yasuo

AU - Nishihara, Tatsuji

AU - Yamato, Kenji

PY - 2003/11

Y1 - 2003/11

N2 - Human papillomavirus type 16 (HPV16), a causative agent of cervical cancers, encodes the E6 and E7 oncogenes, whose simultaneous expression is pivotal for malignant transformation and maintenance of malignant phenotypes. In the hope of developing a gene-specific therapy for HPV-related cancer, we examined the effects of E6 short-interfering RNA (siRNA) on the expression of these oncogenes and on the cell growth of HPV16-related cervical cancer cells. Using SiHa cervical cancer cells, we demonstrated that E6 siRNA decreased the levels of mRNA encoding E6 as well as that encoding E7 protein and also induced nuclear accumulation of p53, the most important target of E6. E6 siRNA suppressed monolayer and anchorage-independent growth of SiHa cells, which was associated with p21CIP1/WAF1 induction and hypophosphorylation of retinoblastoma protein. Further, SiHa cells treated with E6 siRNA formed tumors in NOD/SCID mice that were significantly smaller than in those treated with control siRNA. Our results show HPV E6 siRNA as a candidate for gene-specific therapy for HPV-related cervical cancer.

AB - Human papillomavirus type 16 (HPV16), a causative agent of cervical cancers, encodes the E6 and E7 oncogenes, whose simultaneous expression is pivotal for malignant transformation and maintenance of malignant phenotypes. In the hope of developing a gene-specific therapy for HPV-related cancer, we examined the effects of E6 short-interfering RNA (siRNA) on the expression of these oncogenes and on the cell growth of HPV16-related cervical cancer cells. Using SiHa cervical cancer cells, we demonstrated that E6 siRNA decreased the levels of mRNA encoding E6 as well as that encoding E7 protein and also induced nuclear accumulation of p53, the most important target of E6. E6 siRNA suppressed monolayer and anchorage-independent growth of SiHa cells, which was associated with p21CIP1/WAF1 induction and hypophosphorylation of retinoblastoma protein. Further, SiHa cells treated with E6 siRNA formed tumors in NOD/SCID mice that were significantly smaller than in those treated with control siRNA. Our results show HPV E6 siRNA as a candidate for gene-specific therapy for HPV-related cervical cancer.

KW - Cell growth

KW - E6

KW - E7

KW - HPV16

KW - NOD/SCID mouse

KW - p53

KW - Rb

KW - RNAi

KW - siRNA

KW - Tumor formation

UR - http://www.scopus.com/inward/record.url?scp=0348133602&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0348133602&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2003.08.004

DO - 10.1016/j.ymthe.2003.08.004

M3 - Article

VL - 8

SP - 762

EP - 768

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

IS - 5

ER -